GENEVA (Web Desk) – Cardiovascular diseases (CVDs) are the number one cause of deaths globally claiming more lives annually than from any other cause, according to a report by World Health Organization (WHO).
CVD is a major complication of diabetes and the leading cause of early death among people with diabetes – about 65 per cent of people with diabetes die from heart disease and stroke.
Studies have revealed that the number of cases of diabetes is increasing at an alarming rate globally and especially in the Middle East. 387 million people have diabetes in the world and more than 37 million people in the Mena; by 2035 this will rise to 68 million, the Mail Online reported.
Diabetes has increasingly become a lifestyle-related disease as it afflicts young and old and almost 90 per cent of people living with Type-2 diabetes are overweight or are obese.
Many middle- and low-income countries have more people under the age of 60 with diabetes compared to the world average.
Meanwhile, for high-income countries, a growing population over the age of 60 makes up the largest proportion of diabetes prevalence. As the number of patients grows across the globe, there has never been a stronger and more urgent need for novel therapeutic measures in clinical and preclinical evaluation, that arrest the growth of the disease.
Most cardiovascular diseases can be prevented by addressing behavioural risk factors such as tobacco use, unhealthy diet and obesity, physical inactivity and harmful use of alcohol using population-wide strategies.
People already diagnosed with cardiovascular disease and even those who are at high cardiovascular risk, need early detection and management using counseling and medicines. Raising awareness about this deadly disease will encourage people to adopt healthier lifestyles
The diabetes market, consisting mainly of Type 1 and Type 2 diabetes, is large and growing significantly. The global market value for diabetes therapies and diagnostics has reached to $48.5 billion.
The largest segment of the market, insulin products, is worth $20.8 billion in the recent times, including administration and diagnostic devices. Monitoring devices and other related equipment, the second-largest market is established with an investment of $13.5 billion in which was proposed for $11.3.
The fastest-growing segment of oral hypoglycemic drugs manufacturing funding is $14.13 in present scenario of diabetes market.
